Trials / Not Yet Recruiting

Not Yet RecruitingNCT07428616

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Status: Not Yet Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 100 (estimated)

Sponsor: Exelixis · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Conditions

Meningioma

Interventions

Type	Name	Description
DRUG	Zanzalintinib	Administered as specified in the treatment arm.

Timeline

Start date: 2026-05-01
Primary completion: 2028-02-01
Completion: 2029-09-01
First posted: 2026-02-24
Last updated: 2026-02-24

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT07428616. Inclusion in this directory is not an endorsement.